Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002322 · ClinicalTrials.gov registry record · Phase 2
A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients
A Phase 2 study, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002322: Completed Phase 2 study, sponsored by Pharmacia and Upjohn.
NCT00002322 is a Phase 2 study that has completed, run by Pharmacia and Upjohn. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002322, a Phase 2 study, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
To determine the tolerance and antiviral response of two different doses of atevirdine mesylate (U-87201E) in symptomatic HIV-positive patients with CD4 counts of 50-350 cells/mm3, who also take zidovudine (AZT).
Interventions
- DRUG Zidovudine
- DRUG Atevirdine mesylate
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002322
The ClinicalTrials.gov registry entry for NCT00002322 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pharmacia and Upjohn, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zidovudine is the first listed.
NCT00002322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002322 about?
NCT00002322 is a clinical study titled "A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients". To determine the tolerance and antiviral response of two different doses of atevirdine mesylate (U-87201E) in symptomatic HIV-positive patients with CD4 counts of 50-350 cells/mm3, who also take zidovudine (AZT).
What is the current status of trial NCT00002322?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00002322?
The interventions under investigation include: Zidovudine (DRUG), Atevirdine mesylate (DRUG).
Who is sponsoring clinical trial NCT00002322?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.